OQROGet OQRO Pro
Insider trade

Cadrenal Therapeutics (CVKD)CEO sold ~$7.3K

Quang X Pham, CEO at Cadrenal Therapeutics, sold ~$7.3K of Cadrenal Therapeutics shares.

~$7.3K
Approx. value · 2,277 sh @ $3.20
117K
Holds after · shares reported
Traded
Jun 23, 2026
Filed
Jun 24, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 7, 2026Company filing · Form 8-K · ResultsReported its results
  2. May 11, 2026InsiderCEO sold ~$37K of CVKD shares in the open market
  3. May 12, 2026InsiderCEO sold ~$17K of CVKD shares in the open market
  4. May 22, 2026InsiderCEO sold ~$6.6K of CVKD shares in the open market
  5. May 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 28, 2026, Cadrenal Therapeutics, Inc. (the “Company”) and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.”
  6. May 28, 2026InsiderCEO sold ~$15K of CVKD shares in the open market
  7. May 29, 2026InsiderCEO sold ~$1.5K of CVKD shares in the open market
  8. Jun 2, 2026InsiderCEO sold ~$1.6K of CVKD shares in the open market
  9. Jun 3, 2026InsiderCEO sold ~$9.9K of CVKD shares in the open market
  10. Jun 4, 2026InsiderCEO sold ~$17K of CVKD shares in the open market
  11. Jun 5, 2026InsiderCEO sold ~$9.1K of CVKD shares in the open market
  12. Jun 8, 2026InsiderCEO sold ~$26K of CVKD shares in the open market
  13. Jun 9, 2026InsiderCEO sold ~$53K of CVKD shares in the open market
  14. Jun 10, 2026InsiderCEO sold ~$15K of CVKD shares in the open market
  15. Jun 11, 2026InsiderCEO sold ~$6K of CVKD shares in the open market
  16. Jun 12, 2026InsiderCEO sold ~$51K of CVKD shares in the open market
  17. Jun 15, 2026InsiderCEO sold ~$13K of CVKD shares in the open market
  18. Jun 16, 2026InsiderCEO sold ~$11K of CVKD shares in the open market
  19. Jun 17, 2026InsiderCEO sold ~$1.6K of CVKD shares in the open market
  20. Jun 22, 2026InsiderCEO sold ~$33K of CVKD shares in the open market
  21. Jun 23, 2026 · this disclosureInsiderCEO sold ~$7.3K of CVKD shares in the open market

What came next

  1. Jun 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 25, 2026, the Board of Directors (the “Board”) of Cadrenal Therapeutics, Inc. (the “Company”) appointed John P. Sharp as Interim Chief Financial Officer of the Company.”
  2. Jun 25, 2026InsiderCEO sold ~$6.4K of CVKD shares in the open market
  3. Jun 26, 2026InsiderCEO sold ~$28K of CVKD shares in the open market
  4. Jun 29, 2026InsiderCEO sold ~$22K of CVKD shares in the open market
  5. Jun 30, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  6. Jul 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 7, 2026, James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc. (the “Company”), advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the “Separation Date”).”
  7. Jul 14, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 14, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a confidential separation agreement and general release (the “Separation Agreement”), dated as of July 9, 2026, with James J. Ferguson III, the Company’s Chief Medical Officer.”
  8. Aug 13, 2026Company filing · Form 8-K · ResultsReported its results
  9. Sep 24, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On September 24, 2026, Cadrenal Therapeutics, Inc. (the “Company”), held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cadrenal Therapeutics

OQRO holds no insider, Congress, fund or contract record for Cadrenal Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CVKD page.

Other recent filings by Quang X Pham, Chairman, CEO and Interim CFO

The full history of Quang X Pham, Chairman, CEO and Interim CFO is on the profile page.

How this filing works

Other disclosures at Cadrenal Therapeutics

Everything OQRO holds on this company is on its CVKD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data